STAT+: Pharmalittle: Novavax sees delay in seeking emergency use of its Covid-19 shot; AstraZeneca CEO’s pay causes a stink
Good morning, everyone, and welcome to another working week. We hope the weekend respite was…
Category: STAT+
STAT+: HHS plans to open up billions in hospital Covid-19 grants in coming weeks
WASHINGTON — The Biden administration plans to open applications for billions of dollars in grants…
Opinion: STAT+: The pharma industry needs to measure patient experience from the patients’ perspectives
The relationship between clinical outcomes and the patient experience — the sum of all of…
STAT+: Why health tech companies are investing so heavily in care teams
Kristen Campbell often felt like she was treating patients without all the pieces of the…
STAT+: Eli Broad’s medical research legacy will ‘touch almost the whole world’
Among scientists around the world, Eli Broad’s name will forever be tied to the role…
STAT+: WHO, international regulatory group urge pharma to publish clinical study reports
In a significant step toward greater transparency, the World Health Organization and the International Coalition…
STAT+: How David beat Goliath: Advocacy groups seized a moment, and found allies, in bid to loosen vaccine patent rights
WASHINGTON — They’ve plastered a pharmaceutical CEO’s face on the side of a rented truck…
STAT+: Moderna’s CEO says he ‘didn’t lose a minute of sleep’ over potential waiver of vaccine patents
Moderna chief executive Stephane Bancel on Thursday shrugged off the Biden administration’s support for suspending…
STAT+: Pharmalittle: Pfizer seeks full FDA approval for its Covid-19 shot; EU is willing to explore Covid-19 IP waiver
And so, another working week will soon draw to a close. Not a moment too…
STAT+: Two drug makers, two commercial launches — with divergent results
Biocryst Pharma did it. Aurinia Pharma did not. The “it” is a successful, commercial drug…
STAT+: CRISPR Therapeutics, Nkarta to jointly develop engineered natural killer cells as cancer treatments
Off-the-shelf treatments for cancer made from genetically engineered T cells and natural killer, or NK,…
STAT+: Amazon Care signs first customer for burgeoning health business
Amazon Care signed its first enterprise customer this week, a significant milestone as the virtual-first…
STAT+: The U.S. opened pandora’s box on IP waivers for Covid-19 vaccines. What happens now?
In a surprising move, the Biden administration has said it will support a controversial proposal…
STAT+: Dyno raises $100 million to bring artificial intelligence to gene therapy
Dyno Therapeutics, a Cambridge biotech that uses artificial intelligence techniques to develop gene therapies, said…
.jpg)
STAT+: In Belgium, too many clinical trial sponsors waffle about reporting required results
The results of more than one-fifth of clinical trials that were conducted in Belgium have…
STAT+: Pharmalittle: Biden supports WTO proposal on Covid-19 vaccine IP; Biogen Alzheimer’s drug is cost-effective at $2,500
Good morning, everyone, how are you today? We are doing just fine, thank you, as…
STAT+: Incyte pays $12.6 million to resolve claims it paid drug kickbacks through charity
Incyte (INCY) agreed to pay $12.6 million to settle allegations that donations amounted to kickbacks…
Opinion: STAT+: Faster approval of complex generics is central to affordable, equitable care
The push to improve Americans’ use of effective and less-expensive generic medications is getting a…
STAT+: ‘In their own bubble’: How a cancer center promoted an exclusive experimental drug to attract patients
A new medication for children with a rare and life-threatening cancer called neuroblastoma had a…
STAT+: Biogen’s Alzheimer’s drug may only be cost effective at $2,500 a year
The controversial, but widely anticipated Biogen (BIIB) treatment for Alzheimer’s would only be cost-effective if…
STAT+: Pharmalittle: Pharma showers a key Democratic senator with cash; Lilly exec accused of altering factory documents
Top of the morning to you. Another busy day is unfolding here on the Pharmalot…
STAT+: The long wait for Cel-Sci to finally admit its cancer drug doesn’t work
Eventually, Cel-Sci will have to disclose the results of its Phase 3 cancer clinical trial….
STAT+: Roger Perlmutter, former Merck R&D head, becomes CEO of super-microscopy startup
Roger Perlmutter, previously the head of research at Merck, said Wednesday he will become the…
STAT+: Pharma showers Menendez with rare, off-cycle burst of campaign cash as Democrats eye drug pricing reforms
WASHINGTON — Sen. Bob Menendez doesn’t face reelection until 2024, but pharmaceutical executives are already…
STAT+: Affinia Therapeutics raises $110 million for gene therapy treatments
Affinia Therapeutics, a Waltham-based biotech working on gene therapies to treat diseases using technology developed…
STAT+: Rising wholesale drug prices really do matter to half of all commercially insured Americans
Although the pharmaceutical industry argues that wholesale prices do not accurately reflect prescription drug costs,…
STAT+: Pharmalittle: Pfizer Covid-19 vaccine to generate $26 billion in 2021 sales; EMA reviews Sinovac Covid-19 vaccine
Rise and shine, everyone, another very busy day awaits. Even so, there is nothing like…
.jpg)
STAT+: Gilead sues Russia over a compulsory license issued to a company making remdesivir
Amid worldwide clamoring for Covid-19 vaccines and other therapies, Gilead Sciences (GILD) last month filed…
STAT+: Biden’s Medicaid pressure tactics could put his team at odds with hospitals
WASHINGTON — The Biden administration is pressuring states to expand Medicaid — and it’s setting…
STAT+: How a startup beat health care heavyweights to win Medicare’s AI contest
A $1 million government contest to predict health problems with artificial intelligence attracted the heavyweights…
STAT+: European Commission fines a Merck KGaA unit for providing misleading info prior to a merger
The European Commission fined a unit of Merck KGaA $9 million for providing incorrect or…
STAT+: Roivant Sciences to go public through $7.3 billion SPAC deal
Roivant Sciences, the biotech company once pitched as a Berkshire Hathaway for the pharmaceutical industry,…
STAT+: Pharmalittle: U.S. trade rep to talk with WTO about IP and Covid-19 vaccines; WHO’s Tedros plans to seek re-election
Good morning, everyone, and welcome to another working week. We hope the weekend respite was…
STAT+: Sarepta’s more potent Duchenne treatment shows promise, greater toxicity, in small study
Sarepta Therapeutics said Monday that a second-generation medicine for patients with a certain type of…
Opinion: STAT+: How the FDA’s ‘master plan’ will affect NIH funding for digital medicine projects
The term B.C. took on a new meaning — Before Covid — last year when…
STAT+: Amgen’s KRAS cancer drug had a bad week, but worry about pricing, not safety
Investors do not like surprises with negative overtones, so they reacted badly when Amgen announced…
STAT+: Eli Broad, whose gift established a science powerhouse, dies at 87
Eli Broad, the billionaire entrepreneur whose philanthropy enabled the creation of the Broad Institute of…
STAT+: Brazilian senate votes to suspend patents in bid to widen access to Covid-19 vaccines
After a year of politicking, the Brazilian senate passed a bill that would permit the…
STAT+: U.S. government has invested $6 billion in Moderna’s Covid-19 vaccine
The federal government has now invested about $6 billion in the Covid-19 vaccine from Moderna,…
STAT+: Pharmalittle: Wyden goes back to the drawing board on drug pricing; Emergent undergoes an executive shake-up
And so, another working week will soon draw to a close. Not a moment too…
STAT+: Top Senate Democrat heads back to drawing board on drug pricing
WASHINGTON — A powerful Democratic committee chair is starting to work on a new drug…
Opinion: STAT+: Improving health care means improving data diversity. Federated learning can help
Many companies are developing innovative artificial intelligence solutions for health care. Too often, though, these…
STAT+: Did someone say patent thicket? AbbVie CEO to testify before Congress about drug pricing tactics
As part of its probe into pharmaceutical industry pricing tactics, a Congressional committee next month…
STAT+: Global spending on medicines could hit $1.6 trillion by 2025 — and that doesn’t include Covid-19 vaccines
Global spending on medicines is forecast to grow between 3% and 6% annually and reach…
STAT+: Lander fends off controversy, pledges broader access to STEM careers during Senate confirmation hearing
WASHINGTON — Eric Lander, President Biden’s nominee to lead the White House’s science policy office,…
STAT+: Pharmalittle: Biden issues ’empty call’ for drug pricing reform; FDA threatens to fine company for not posting trial results
Top of the morning to you, and a fine one it is. Gray skies are…
STAT+: 5 startups seizing the moment to shake up the electronic health record industry
The road to shake up the health record industry is littered with failures. But a…
STAT+: Uber names a new head of its growing health business
Uber hailed a new lead for its expanding health business on Thursday, naming Caitlin Donovan…
STAT+: Americans paid two to four times as much for some drugs as in three other countries
Amid national angst over the cost of prescription drugs, a new analysis finds that U.S….
STAT+: For the first time, the FDA may fine a drug maker for failing to post clinical trial results
The Food and Drug Administration is threatening to fine Acceleron Pharma (XLRN) for failing to…